Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma

The Lancet

Volumn 343, Issue 8907, 1994, Pages 1177-1183

  Riethmuller G ^a   Gruber, R ^a   Schneider Gadicke E ^a   Schlimok, G ^b   Witte, J ^b   Raab, R ^c   Pichlmayr, R ^c   Pichlmaier, H ^d   Schmiegel, W ^e   Buggisch, P ^e   Hoffken K ^f   Hirche, H ^g   Pichimayr, Rudolf ^b   Buggisch, Peter ^b   Witte, Jens ^b   German Cancer Aid 17 1A Study Group, ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b Tumorzentrum Munchen an den Medizinischen Fakultaten der Ludwig Maximilians Universitat der Technischen Universität München ^*

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Medizinische Klinik Universitätskrankenhaus Eppendorf Hamburg Germany ^*  (United Kingdom)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERMANY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

EID: 0028224082     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)92398-1     Document Type: Article

References (32)

1. Clinical perspectives on human colorectal cancer metastases
2. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers
3. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
4. The therapeutic use of monoclonal antibodies in colorectal carcinoma
5. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies
6. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody
7. Colorectal carcinoma antigens detected by hybridoma antibodies
8. The epithelial cell surface antigen 17-1A a target for antibody-mediated tumour therapy its biochemical nature tissue distribution and recognition by different monoclonal antibodies
9. Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker
10. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2
11. Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA
12. Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein
13. Release of monoclonal antibody-defined antigens by human colorectal carcinoma and melanoma cells
14. The randomisation and stratificaiton of patients to clinical trials
15. A new design for randomized clinical trials
16. Effective surgical adjuvant therapy for high-risk rectal carcinoma
17. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01
18. Immunotherapy of gastrointestinal malignancies with a murine IgG2A antibody
19. Current applications of monoclonal antibodies for the therapy of hematopoietic cancers
20. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumours
21. Immunological analysis of micrometastases and the metastatic phenotype of human tumours
22. Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens
23. Antibodies as antigens: the use of mouse monoclonal antibodies to focus human T cells against selected targets
24. IgG2a monoclonal antibodies inhibit human tumour growth through interaction with effector cells
25. Tumour-growth suppression in nude mice by a murine monoclonal antibody: factors hampering successful therapy
26. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen
27. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
28. Micrometastatic tumour cells in bone marrow in colorectal cancer
29. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
30. Breast cancer
31. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
32. Continuous cultures of fused cells secreting antibody of predefined specificity